D016 TECHNOLOGY
D016.
A defined recombinant hyaluronidase technology platform.
Developed for application-specific quality, controlled supply and pharmaceutical development pathways.
Representational biotechnology visual · not a molecular structure of D016
THE TECHNOLOGY
One Core Asset. Defined Development Paths.
D016 is Pharmact’s core recombinant hyaluronidase technology. It combines defined enzymatic characteristics with an application-specific quality and development strategy.
D016 is not presented as one undifferentiated finished product. Specifications, documentation, manufacturing controls and regulatory requirements are defined according to intended use and development stage.
D016 – CORE ASSET
A Defined Biotechnology Asset
Recombinant protein technology with high specific enzymatic activity and application-specific purity specifications.
Technical characterization is separated from pharmaceutical claims. Product-specific use, safety, efficacy and regulatory status require their own evidence and development pathway.
DEFINED TECHNICAL CHARACTERISTICS
Specifications Are Interpreted in Context.
Public technical values describe the current D016 platform at an appropriate level of abstraction. Final release specifications remain configuration- and application-specific.
Recombinant hyaluronidase protein platform with dual enzymatic activity.
Approximately ≥1.2 million IU/mg under defined assay conditions.
Application-specific: approximately ≥95% for selected industrial/cosmetic development configurations; pharmaceutical development targets approximately ≥99%.
Recombinant protein; non-animal-derived technology platform.
DESIGNED DUAL ACTIVITY
Designed PH20-like / HYAL4-like Dual Activity.
D016 was designed with a dual-activity profile combining PH20-like and HYAL4-like enzymatic functions within a single recombinant protein platform. Pharmact considers this functional combination a key differentiating feature of the D016 technology platform.
Evidence boundary. Functional differentiation does not establish superior therapeutic performance or clinical benefit.
MANUFACTURING STRATEGY
Scalability Without Unnecessary Process Disclosure.
Pharmact’s manufacturing strategy is designed around controlled recombinant production and future scale-up. Public information is intentionally limited to what is relevant for understanding the technology platform.
01
RECOMBINANT PRODUCTION
D016 is produced using recombinant biotechnology rather than animal-derived source material.
02
SCALABLE PLATFORM
A Bacillus subtilis-based manufacturing platform is under development as a scalable production route.
03
CONTROLLED DISCLOSURE
Detailed proprietary expression, purification and process information is not part of the public website.
APPLICATION-SPECIFIC DEVELOPMENT
One Technology. Different Requirements.
D016 is advanced through clearly separated pathways rather than by transferring one quality or claim set across all applications.
DEVELOPMENT PATHWAYS
D016 Connects Technology, Development and Partnering.
01
BELACT
Lead pharmaceutical development program using D016 in a separately controlled therapeutic development pathway.
02
PARTNERING & LICENSING
Evaluation, supply and commercial rights are structured according to intended use, quality requirements and partner scope.
03
TOPICAL COSMETIC PATHWAY
RECELURA represents a separate topical cosmetic development pathway with its own finished-product assessment and regulatory responsibilities.
DEVELOPMENT STATUS
D016 is a biotechnology asset used in research, development, supply and application-specific programs. References to pharmaceutical development do not mean that D016 or BELACT is an approved medicinal product. Safety and efficacy for therapeutic use require the applicable nonclinical, clinical and regulatory development program.
D016 ACCESS
Discuss a Defined D016 Requirement
Pharmact engages with scientific, industrial and pharmaceutical partners where intended use, technical requirements and required rights can be defined clearly.